Atlas Trials

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Clinical trial NCT04455503 · TERMINATED

Trial details

NCT number
NCT04455503
Sponsor
Evaxion Biotech A/S
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Melanoma Stage IVMelanoma Stage III
Start date
2020-07-13
Primary completion
2023-02-28
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.